No Manufacturer Listed

RECOMBITEK® Equine West Nile Virus contains a lyophilized recombinant canarypox vectored West Nile Virus vaccine plus a sterile liquid diluent. A canarypox vector has been modified using recombinant technology to express the desired antigens capable of stimulating a protective immune response to West Nile Virus. After inoculation, the vector does not multiply in the horse, but does express the protective proteins. As a consequence, these components induce an immune status against West Nile Virus. Safety and immunogenicity of this vaccine have been demonstrated by vaccination and challenge tests in susceptible horses.

Reconstitute the lyophilized vaccine with accompanying liquid diluent and aseptically inject a 1 ml dose by intramuscular route. For primary vaccination, revaccinate with a second 1 ml dose of this product 4 to 6 weeks later. Annual revaccination with a single dose is recommended.